STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma-Reference-Cited by-同舟云学术

STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma

Published:2024-06-17 Issue:12 Volume:134 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Najem Hinda^ORCID,Lea Spencer T.,Tripathi Shashwat,Hurley Lisa,Chen Chao-Hsien,William Ivana,Sooreshjani Moloud,Bowie Michelle,Hartley Genevieve,Dussold Corey,Pacheco Sebastian,Dmello Crismita^ORCID,Lee-Chang Catalina^ORCID,McCortney Kathleen^ORCID,Steffens Alicia,Walshon Jordain,Ott Martina,Wei Jun^ORCID,Marisetty Anantha,Balyasnikova Irina,Stupp Roger^ORCID,Lukas Rimas V.,Hu Jian^ORCID,James Charles David^ORCID,Horbinski Craig M.^ORCID,Lesniak Maciej S.^ORCID,Ashley David M.,Priebe Waldemar,Platanias Leonidas C.,Curran Michael A.^ORCID,Heimberger Amy B.^ORCID

Funder

NIH Clinical Center

Charlie Teo Foundation

National Center of Advancing Translational Science

Joan Traver Walsh Family Foundation

Dr. Marnie Rose Foundation

Brockman Foundation

CPRIT Research Training Award

Publisher

American Society for Clinical Investigation

Link

https://www.jci.org/articles/view/175033/files/pdf

Reference57 articles.

1. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

2. Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice

3. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

4. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

5. The possibility of cancer immune editing in gliomas. A critical review